复星医药子公司启动复迈宁®儿童脑胶质瘤Ⅲ期临床试验

财中社2025-07-09

7月9日，复星医药（600196/02196）发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®（芦沃美替尼片）用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。截至2025年5月，该药品的累计研发投入约为6.07亿元（未经审计）。目前，该药品在中国境内已上市并获批两项...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550069684?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-09 16:37","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550069684","market":"hk","top_or_hot":-1,"title":"复星医药子公司启动复迈宁®儿童脑胶质瘤Ⅲ期临床试验","media":"财中社","content":"<div>\n<p>7月9日，复星医药（600196/02196）发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®（芦沃美替尼片）用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。截至2025年5月，该药品的累计研发投入约为6.07亿元（未经审计）。目前，该药品在中国境内已上市并获批两项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药子公司启动复迈宁®儿童脑胶质瘤Ⅲ期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药子公司启动复迈宁®儿童脑胶质瘤Ⅲ期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-09 16:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月9日，复星医药（600196/02196）发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®（芦沃美替尼片）用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。截至2025年5月，该药品的累计研发投入约为6.07亿元（未经审计）。目前，该药品在中国境内已上市并获批两项...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b","article_id":"2550069684","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709163825953bec38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550069684","pubTimestamp":1752050252,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月9日，复星医药发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。与此同时，该药品用于成人Ⅰ型神经纤维瘤病和儿童低级别脑胶质瘤的临床试验均处于Ⅲ期阶段，涉及的其他适应症也在进行相关临床试验。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK1576":"医药外包概念","BK1593":"医美概念股","BK1191":"制药","03347":"泰格医药","BK1515":"抗疫概念","02196":"复星医药"},"translate_title":"Fosun Pharma subsidiary launches Fumainin ® Phase III clinical trial of childhood glioma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"02196":1},"content_text":"7月9日，复星医药（600196/02196）发布公告，控股子公司药品临床试验进展情况。公告指出，该公司控股子公司上海复星医药产业发展有限公司已启动复迈宁®（芦沃美替尼片）用于治疗儿童低级别脑胶质瘤的Ⅲ期临床试验。该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。截至2025年5月，该药品的累计研发投入约为6.07亿元（未经审计）。目前，该药品在中国境内已上市并获批两项适应症，分别为朗格汉斯细胞组织细胞增生症及儿童伴有症状的丛状神经纤维瘤。与此同时，该药品用于成人Ⅰ型神经纤维瘤病和儿童低级别脑胶质瘤的临床试验均处于Ⅲ期阶段，涉及的其他适应症也在进行相关临床试验。根据IQVIAMIDAS™数据，2024年MEK1/2选择性抑制剂的全球销售额约为20.68亿美元。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550069684","isCrawlerRequest":true}